| Pooled relative frequency | 95 % confidence interval | I2 statistic |
---|---|---|---|
Conjunctival bleeding/injection and conjunctivitis | |||
Eastern–Central Africa (8 studies) | 45.3 % | 34.7–56.1 % | 70.7–91.6 % |
Eastern–Central Africa (Zaire Ebolavirus, 6 studies) | 45.4 % | 32.6–58.4 % | 77.9–94.2 % |
West Africa (5 studies) | 18.0 % | 6.0–34.5 % | 95.6–98.3 % |
Conjunctival bleeding/injection only | |||
Eastern–Central Africa (3 studies) | 38.2 % | 33.0–43.6 % | 0.0–95.5a |
West Africa (2 studies) | 18.8 % | 11.0–28.8 % | 0.0–91.3a |
Conjunctivitis only | |||
Eastern–Central Africa (5 studies) | 50.0 % | 31.0–68.2 % | 72.0–94.0 % |
West Africa (3 studies) | 17.9 % | 3.0–41.5 % | 95.6–99.2 % |
Nasal bleeding | |||
Eastern–Central Africa (8 studies) | 10.6 % | 5.7–16.8 % | 33.1–84.8 % |
Eastern–Central Africa (Zaire Ebolavirus, 5 studies) | 9.0 % | 3.3–17.2 % | 47.7–90.9 % |
West Africa (2 studies) | 1.3 % | 1.0–1.8 % | 0.0–92.8 %a |
Gingival bleeding | |||
Eastern–Central Africa (10 studies) | 24.2 % | 11.9–39.2 % | 93.6–97.0 % |
Eastern–Central Africa (Zaire Ebolavirus, 7 studies) | 27.9 % | 12.5–46.7 % | 95.1–97.9 % |
West Africa (1 study) | 1.9 % | 1.4–2.4 % | Not applicableb |